<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1004">
  <stage>Registered</stage>
  <submitdate>23/01/2006</submitdate>
  <approvaldate>25/01/2006</approvaldate>
  <actrnumber>ACTRN12606000035527</actrnumber>
  <trial_identification>
    <studytitle>Recurrence of varicose veins following superficial venous surgery - mechanism and prevention.</studytitle>
    <scientifictitle>Recurrence of varicose veins following superficial venous surgery - mechanism and prevention.</scientifictitle>
    <utrn />
    <trialacronym>The Patch Study</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Recurrence of varicose veins</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A randomised controlled prospective study of the use of a mechanical barrier to prevent neovascularisation recurrence of varicose veins following surgery. Two groups will be compared.
- Group A: Complete surgical correction of venous reflux based on duplex ultrasound mapping and routine surgical techniques.
- Group B: Treatment group: As for Group A plus surgical patch (PTFE) placed over the ligated saphenofemoral junction to obstruct new vessel formation.
- Follow up of all patients (ultrasound, air plethysmography and clinical evaluation) for 5 years: 1 month, 6 months, 1 year, 3 years and 5 years.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The recurrence of ultrasound detected venous reflux at the ligated saphenofemorl junction site in the groin due to neovascularisation.</outcome>
      <timepoint>Outcome measured at all follow up timepoints.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical recurrence</outcome>
      <timepoint>Evaluated at each time interval.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Venous clinical severity score</outcome>
      <timepoint>Evaluated at each time interval.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient satisfaction questionnaire.</outcome>
      <timepoint>Evaluated at each time interval.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Clear indication for superficial cein surgery (primary or recurrent)- Reasonable expectation for good compliance over study period.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Life expectancy less than two years after surgery- Inaccessible distance from Dunedin- Severe immobility.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation: Not recorded in patients record or operative account, not told to patient, not recorded in research follow up protocols, surgeons do not communicate allocation to assessment staff. Envelopes, which contain the number indicating type of treatment the patient will receive, will be opened at time of  surgery. An independant person will randomise, administer and maintain the randomisation and code until analyses complete.</concealment>
    <sequence>Randomisation by random numbers in blocks for each participating surgeon. Envelopes, which contain the number indicating type of treatment the patient will receive, will be opened at the time of surgery. An independent person will randomise, administer and maintain the randomisation and code until analyses complete. Random numbers are computer generated. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/06/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Department of Surgery, Dunedin School of Medicine</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Otago Medical Research Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Department of Surgery, Dunedin School of medicine</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>New Zealand Lottery Board Medical Research</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Regional Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Andre van Rij</name>
      <address>Department of Surgery
Dunedin School of Medicine
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 ext. 8834</phone>
      <fax />
      <email>andre.vanrij@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Andre van Rij</name>
      <address>Department of Surgery
Dunedin School of Medicine
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 ext. 8834</phone>
      <fax />
      <email>andre.vanrij@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>